Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Teva and Active Biotech remain committed to the development of NERVENTRA® (laquinimod) for multiple sclerosis following the negative opinion from the EMA's CHMP
Gait Mechanics are Different between Healthy Controls and Patients with Multiple Sclerosis.
Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.
[Neuromyelitis optica following thymectomy with severe spinal cord atrophy after frequent relapses for 30 years].
Glatiramer acetate ameliorates experimental autoimmune neuritis.
Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.
European Commission Approves Genzyme’s Once-Daily, Oral Multiple Sclerosis Treatment Aubagio® (teriflunomide)
[The membrane stabilizing effect of glatiramer acetate in multiple sclerosis].
Genzyme receives positive CHMP opinion in the European Union for once-daily, oral AUBAGIO® to treat relapsing-remitting multiple sclerosis
Recurrent brainstem lesions mimicking infarctions in an elderly patient with neuromyelitis optica spectrum disorder.
LC-MS/MS determination of FTY720 and FTY720-phosphate in murine intracellular compartments and human plasma.
Dynamic imaging of individual remyelination profiles in multiple sclerosis.
Cutaneous adverse events in multiple sclerosis patients treated with daclizumab.
Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.
Biogen Idec receives negative opinion from the CHMP on Fampyra
Iron content of the pulvinar nucleus of the thalamus is increased in adolescent multiple sclerosis.
Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results.
Molecular mechanism underlying the impact of vitamin D on disease activity of MS.
The Clinical Meaning of Walking Speed as Measured by the Timed 25-Foot Walk in Patients With Multiple Sclerosis.
Reviewing the Unmet Needs of Patients with Multiple Sclerosis.
The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial.
Synthetic Biologics Reports Results of Independent Third Party Evaluations of Trimesta™ Data from Investigator-Sponsored Phase 2 Clinical Trial for Relapsing-Remitting Multiple Sclerosis
Cyclophosphamide
New approaches in the management of multiple sclerosis.
Oligodendrocyte death results in immune-mediated CNS demyelination.

Pages